Pigment epithelium-derived factor (PEDF), a glycoprotein with neuronal differentiating activity, possesses antiinflammatory properties both in cell culture and animal models. However, the relationship between serum levels of PEDF and high-sensitivity C-reactive protein (hs-CRP), one of the representative biomarkers for inflammation in humans, is largely unknown. This study investigated whether serum PEDF levels were associated with hs-CRP in 120 apparently healthy unmedicated Japanese subjects (93 males, 27 females; mean age 58.0 years). All subjects underwent a complete history and physical examination, including blood chemistries, anthropometric and metabolic variables. Multiple regression analysis found that serum hs-CRP, creatinine and triglyceride levels, and the homeostasis model assessment of insulin resistance (HOMA-IR) and body mass index were significantly and independently associated with serum PEDF levels. It is concluded that, serum levels of PEDF are associated with serum levels of hs-CRP independently of anthropometric, metabolic and renal function variables. The results also suggest that serum PEDF levels may be elevated as a counter-system against subclinical inflammation.
Introduction
Pigment epithelium-derived factor (PEDF), a glycoprotein with potent neuronal differentiating activity, was first purified from the conditioned media of human retinal pigment epithelial cells. 1 We, along with others, have found that PEDF inhibits cytokine and growth factor-elicited endothelial cell damage, reduces vascular hyperpermeability in a rat model of diabetes, and prevents neointimal hyperplasia after balloon injury in rats through its H Umei, S-I Yamagishi, T Imaizumi PEDF and hs-CRP antioxidative properties. 2 -6 These animal studies have indicated that PEDF may be an endogenous anti-inflammatory factor and could exert beneficial effects on atherosclerosis by blocking the inflammatory responses to injuries. In humans, serum PEDF levels have been shown to be elevated in metabolic syndrome in a general population. 7 Because several pro-inflammatory cytokines are activated in metabolic syndrome, it is considered a chronic inflammatory condition. 8 Thus, it is conceivable that the elevation of PEDF in metabolic syndrome may be a counter-system against inflammation in humans. In our previous study, PEDF was marginally, but not significantly, related to serum levels of high-sensitivity C-reactive protein (hs-CRP). 7 There are several possible reasons for this, including the use of medications for hypertension, dyslipidaemia and diabetes. It is known that these medications decrease inflammation and reduce hs-CRP in humans. 8 The serum level of hs-CRP, one of the bestcharacterized biomarkers for low-grade, subclinical inflammation, is elevated in patients with coronary artery disease 9 and is an independent predictor of future cardiovascular events. Moreover, hs-CRP is elevated in proportion to the accumulation of coronary risk factors or the metabolic syndrome in subjects without apparent cardiovascular disease. 10 -13 The present study aimed to determine whether serum levels of PEDF were associated with levels of hs-CRP independently of anthropometric, metabolic and renal function variables in apparently healthy, unmedicated Japanese subjects in order to examine whether PEDF is related to inflammation in humans.
Subjects and methods

SUBJECTS
Individuals without apparent cardiovascular disease who visited a health check programme at Kurume University Hospital in 2005 were enrolled in this study. None had symptomatic coronary artery disease or a family history of premature cardiovascular disease. All female subjects were postmenopausal. The subjects were free from medications and vitamin supplements. Oral informed consent was obtained, and the study protocol was approved by the Institutional Ethics Committee of Kurume University School of Medicine.
STUDY DESIGN AND MEASUREMENTS
All subjects underwent a routine medical evaluation that included a complete history and physical examination, serum chemistries, electrocardiography and chest radiography. Medical and smoking histories were ascertained by questionnaire. Cigarette smokers were defined as subjects who were current smokers or who had ceased tobacco use within 3 months of entry to the study. Height and weight were measured, and body mass index (BMI; body weight in kg/[height in cm] 2 ) was calculated as an indicator of obesity. Blood pressure (BP) was measured in the sitting position using an upright standard sphygmomanometer. Vigorous physical activity and smoking were avoided for at least 30 min before BP measurement.
Blood was drawn from the antecubital vein in the morning after a 12-h fast for the determination of lipids (high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C], and triglycerides [TG]), fasting plasma glucose (FPG), insulin, creatinine, hs-CRP, total antioxidant capacity (TOAC) and PEDF. The TOAC was analysed with a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Calbiochem, La Jolla, CA, USA) according to the manufacturer's H Umei, S-I Yamagishi, T Imaizumi PEDF and hs-CRP instructions. Serum PEDF levels were measured with an ELISA system as described previously. 7 Other blood chemistries were measured at a commercially available laboratory (SRL Inc., Hachioji, Japan), using ELISA or enzymatic assay as described previously. 7 The homeostasis model assessment of insulin resistance (HOMA-IR) index was calculated from the values of fasting plasma glucose (mg/dl) and insulin (µU/ml) using the formula: (glucose × insulin)/405.
STATISTICAL ANALYSES
Mean values with upper and lower 95% confidence intervals were exponentiated and presented as the geometric mean ± SD. All statistical analyses were performed with SPSS version 18 (SPSS ® Inc., Chicago, IL, USA). Gender was coded as dummy variables. Univariate analysis was performed for determinants of serum PEDF levels. To determine independent correlations with PEDF levels, stepwise multiple regression analysis was performed. Statistical significance was defined as P < 0.05.
Results
A total of 120 healthy subjects (93 men, 27 women; mean ± SD age 58.0 ± 9.4 years) without apparent cardiovascular disease were included in the study. Their baseline demographic characteristics are presented in Table 1 . Serum levels of PEDF in men were significantly higher than in women (P < 0.05). Univariate analysis revealed significant correlations of serum PEDF with gender, BMI, waist circumference, HDL-C, serum TG, serum insulin, HOMA-IR index, serum creatinine, mean BP, smoking and serum hs-CRP (Table  2) . Because these significant parameters could Data are mean ± SD, unless stated otherwise. *P < 0.05 for men versus women. BMI, body mass index; PEDF, pigment epithelium-derived factor; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; FPG, fasting plasma glucose; HOMA-IR, homeostasis model assessment of insulin resistance; MBP, mean blood pressure; TAOC, total antioxidant capacity; and hs-CRP, high-sensitivity C-reactive protein.
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be closely correlated with each other, stepwise multiple regression analysis was performed. This found that HOMA-IR, BMI and serum levels of hs-CRP, creatinine and TG correlated independently with PEDF (r 2 = 0.22 overall related to PEDF; Table 3 ).
Discussion
The present study demonstrated that hs-CRP, a biomarker representative for subclinical inflammation, correlates with serum levels of PEDF in apparently healthy, unmedicated subjects, independently of anthropometric, These findings have also extended previous observations that showed serum PEDF levels were associated with the components of metabolic syndrome in a general population and that the levels were significantly higher in patients with end-stage renal disease than in control subjects. 7, 14 Given the fact, therefore, that PEDF possesses antioxidative and anti-inflammatory properties, 2 -6 the present observations support the concept that serum PEDF levels may be elevated as a counter-system against low-grade subclinical inflammation in apparently healthy subjects and that the kidney may be a main organ for the clearance of PEDF in the circulation.
There is accumulating evidence that lowgrade subclinical inflammation, shown by a slight elevation of serum hs-CRP levels, plays a role in the pathogenesis of insulin resistance and the metabolic syndrome. 10 -13 The present study also showed that the anthropometric, metabolic and renal variables of BMI, HOMA-IR index, and serum triglycerides and creatinine, were independently associated with serum PEDF levels in apparently healthy unmedicated subjects. Since PEDF has been shown to improve hepatic insulin resistance in vitro, 15 the present findings indicate that elevation of PEDF may combat inflammation-elicited insulin resistance in humans.
We previously reported that serum hs-CRP levels did not correlate with serum levels of PEDF in a general population. 7 However, in these previous reports, 7 we enrolled subjects who were taking medications for hypertension, dyslipidemia and diabetes. It is well known that these medications decrease inflammation and reduce hs-CRP levels in humans. 16 -18 This difference in subject population could account for the discrepancies between the previous study and the present one.
The present study was cross-sectional, so it was not possible to assess whether the elevation of PEDF was a cause of or a consequence of subclinical inflammation; therefore, the issue of whether serum PEDF levels are elevated as a counter-system against inflammation remains unknown. Future longitudinal and/or interventional studies are needed to resolve these issues. Other than insulin resistance, metabolic syndrome and renal dysfunction, the underlying mechanisms for elevated hs-CRP are not known, so the clinical significance of elevated PEDF also needs to be elucidated by future studies.
